Eleutheroside E
(Synonyms: 刺五加苷E) 目录号 : GN10300
Eleutheroside E (EE)是西伯利亚人参(Acanthopanax senticosus)的主要活性成分，具有抗疲劳、神经保护和免疫调节作用。
Cas No.:39432-56-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Eleutheroside E (EE) is a principal active component of Acanthopanax senticosus that possesses anti-fatigue, neuroprotective and immunomodulatory activities[1].
In vitro, Eleutheroside E (100, 300 and 500μM; 48h) can improve the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -induced apoptosis of PC-12 cells by increasing the mitochondrial membrane potential and reducing the level of intracellular reactive oxygen species (ROS)[2]. Eleutheroside E (25μM; 72h) inhibited the cell viability with promoted apoptosis in Cervical cancer (CC) cells[3]. Eleutheroside E (30, 60 and 100mM; 12h) administration attenuated the cardiomyocyte apoptosis induced by hypoxia-reoxygenation (H/R) injury[4].
In vivo, Pre-treatment with Eleutheroside E (50 and 100 mg/kg; 3 days; i.p.) can improve the pathological manifestations of high-altitude pulmonary edema (HAPE), such as alveolar hemorrhage, thickening of the alveolar walls, inflammatory cell infiltration, and alveolar and interstitial edema, with the effects being positively related to the dose[1]. Supplementation with Eleutheroside E (50 mg/kg/d; 4 weeks) can prevent radiation-induced cognitive impairment and damage of neuron morphology and ultrastructures in the hippocampus of mice[5]. Eleutheroside E (10mg/kg; 20 days; gavage) alleviates cerebral ischemia-reperfusion injury in a 5-hydroxytryptamine receptor 2C (Htr2c)-dependent manner in rats[6].
References:
[1] Shen Z, Huang D, Jia N, Zhao S, Pei C, Wang Y, Wu Y, Wang X, Shi S, Wang F, He Y, Wang Z. Protective effects of Eleutheroside E against high-altitude pulmonary edema by inhibiting NLRP3 inflammasome-mediated pyroptosis. Biomed Pharmacother. 2023 Nov;167:115607.
[2] Yao Y, Liao C, Qiu H, Liang L, Zheng W, Wu L, Meng F. Effect of Eleutheroside E on an MPTP-Induced Parkinson's Disease Cell Model and Its Mechanism. Molecules. 2023 Apr 29;28(9):3820.
[3] Cai Y, Zhang J, Xin T, Xu S, Liu X, Gao Y, Huang H. Eleutheroside E functions as anti-cervical cancer drug by inhibiting the phosphatidylinositol 3-kinase pathway and reprogramming the metabolic responses. J Pharm Pharmacol. 2022 Sep 1;74(9):1251-1260.
[4] Wang S, Yang X. Eleutheroside E decreases oxidative stress and NF-κB activation and reprograms the metabolic response against hypoxia-reoxygenation injury in H9c2 cells. Int Immunopharmacol. 2020 Jul;84:106513.
[5] Song C, Duan F, Ju T, Qin Y, Zeng D, Shan S, Shi Y, Zhang Y, Lu W. Eleutheroside E supplementation prevents radiation-induced cognitive impairment and activates PKA signaling via gut microbiota. Commun Biol. 2022 Jul 8;5(1):680.
[6] Liu Z, Gao W, Xu Y. Eleutheroside E alleviates cerebral ischemia-reperfusion injury in a 5-hydroxytryptamine receptor 2C (Htr2c)-dependent manner in rats. Bioengineered. 2022 May;13(5):11718-11731.
Eleutheroside E (EE)是西伯利亚人参(Acanthopanax senticosus)的主要活性成分，具有抗疲劳、神经保护和免疫调节作用[1]。
体外实验表明，Eleutheroside E (100, 300和500μM; 48h)能够通过增加线粒体膜电位和降低细胞内活性氧（ROS）水平，改善1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)诱导的PC-12细胞凋亡[2]。此外，Eleutheroside E (25μM; 72h)抑制了宫颈癌(CC)细胞的活性，并促进了其凋亡[3]。Eleutheroside E (30, 60和100mM; 12h)减轻了缺氧复氧(Hypoxia-reoxygenation, H/R)损伤诱导的心肌细胞凋亡[4]。
在体内实验中，Eleutheroside E (50和100mg/kg; 3天; 腹腔注射)预处理能够改善高原性肺水肿(HAPE)引起的病理表现，如肺泡出血、肺泡壁增厚、炎症细胞浸润以及肺泡和间质水肿，其效果与剂量呈正相关[1]。Eleutheroside E (50mg/kg/天; 4周)补充能够预防辐射诱导的小鼠海马神经元形态和超微结构的认知障碍和损伤[5]。此外，Eleutheroside E (10mg/kg; 20天; 管饲法)能够以5-羟色胺受体2C (Htr2c)依赖的方式减轻大鼠的脑缺血再灌注损伤[6]。
| Cell experiment [1]: | |
|
Cell lines |
Hela and SiHa |
|
Preparation Method |
After being administered with 0 and 25µM Eleutheroside E, Hela and SiHa cells were collected, washed with phosphate-buffered saline (PBS), resuspended by 0.5ml of bind buffer, and stained with 5µl propidium iodide (PI) and 5µl Annexin V/FITC at room temperature for 15min. The cell apoptosis was analysed on a FACScan flow cytometry using CellQuest software. |
|
Reaction Conditions |
25μM; 72h |
|
Applications |
Eleutheroside E inhibited the cell viability with promoted apoptosis in Cervical cancer (CC) cells. |
| Animal experiment [2]: | |
|
Animal models |
male Sprague-Dawley rats; 100–110g; 4–5 weeks |
|
Preparation Method |
The all 42 rats were divided into the following six groups (n = 7) in a manner of random number table: (1) Sham, (2) Eleutheroside E, (3) HAPE, (4) Eleutheroside E 50mg/kg + HAPE, (5) Eleutheroside E 100mg/kg + HAPE and (6) Eleutheroside E 100mg/kg + Nig 4mg/kg + HAPE groups. Rats in the Sham and HAPE groups were treated with normal saline intraperitoneal injections, whereas those in the other four groups were injected intraperitoneally with corresponding doses of Eleutheroside E for 3 days. Nig, an activator of NLRP3, was used to explore the efficacy of Eleutheroside E on NLRP3-mediated pyroptosis in HAPE. Rats in the (6) group were injected intraperitoneally with Nig 30min before the last dose of Eleutheroside E. |
|
Dosage form |
50 and 100mg/mice; 3 days; i.p. |
|
Applications |
Pre-treatment with Eleutheroside E (50 and 100 mg/kg; 3 days; i.p.) can improve the pathological manifestations of high-altitude pulmonary edema (HAPE), such as alveolar hemorrhage, thickening of the alveolar walls, inflammatory cell infiltration, and alveolar and interstitial edema, with the effects being positively related to the dose. |
|
References: |
|
| Cas No. | 39432-56-9 | SDF | |
| 别名 | 刺五加苷E | ||
| 化学名 | (2R,3S,4R,5R,6S)-2-[4-[6-[3,5-dimethoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| Canonical SMILES | COC1=CC(=CC(=C1OC2C(C(C(C(O2)CO)O)O)O)OC)C3C4COC(C4CO3)C5=CC(=C(C(=C5)OC)OC6C(C(C(C(O6)CO)O)O)O)OC | ||
| 分子式 | C34H46O18 | 分子量 | 742.72 |
| 溶解度 | ≥ 26.2mg/mL in DMSO | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3464 mL | 6.732 mL | 13.464 mL |
| 5 mM | 0.2693 mL | 1.3464 mL | 2.6928 mL |
| 10 mM | 0.1346 mL | 0.6732 mL | 1.3464 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet